REVIEW ARTICLE

International Journal of Clinical Oncology

, Volume 11, Issue 2, pp 82-89

First online:

Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma

  • Shinji TanakaAffiliated withDepartment of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine Email author 
  • , Shigeki AriiAffiliated withDepartment of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Hepatocellular carcinoma (HCC) is well known as a typical angiogenic tumor, especially in the moderately to poorly differentiated type. Such clinicopathological characteristics are not only useful for imaging diagnosis but are also applicable to the treatment of HCC. In addition, recent molecular studies have revealed that angiogenesis is closely related to hepatocarcinogenesis. In this review, the molecular mechanism of HCC angiogenesis and the antiangiogenic prevention of HCC are reviewed to introduce the latest trends in antiangiogenic treatment of cancers, including HCC.

Key words

Hepatocellular carcinoma Angiogenesis Angiogenic switch VEGF Angiopoietin Molecularly targeted antiangiogenic therapy